NEW YORK (GenomeWeb News) – Agilent Technologies announced today that it has acquired the nucleic acid medicines business of Dowpharma for an undisclosed sum.
The acquisition is concurrent with an expansion of its nucleic acid active pharmaceutical ingredient manufacturing facility in Boulder, Colo. Agilent said that it would add large-scale nucleic acid synthesis, purification, and drying capacity to its capabilities by the end of this year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.